Pluri Inc. (PLUR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.08 (+0.00%), Market cap $0.04B, 52-week low–high $2.92 ~ $5.79.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent clau
Financial statements, price targets, institutional (13F) holdings and related news for Pluri Inc. are updated in real time on BlackAll Trade.
Pluri Inc. trades at $1.08 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Pluri Inc. has a market cap of about $0.04B.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops place